IGF-I

BONDY CA, UNDERWOOD LE, CLEMMONS DR, GULER HP, BACH MA, SKARULIS M. Clinical uses of insulin-like growth factor I. Ann Intern Med 1994 120:593-601.

 

CHEETHAM TD, CLAYTON KL, HOLLY JM, TAYLOR AM, CONNORS M, DUNGER DB. In vivo use of recombinant human IGF-I: studies in type I diabetes. In: The insulin-like growth factors and their regulatory proteins, Proceedings of The Third International Symposium on Innsulin-Like Growth Factors, Sydney, 6-10 February 1994, Excerpta medica, Amsterdam, Holland. 1994, pp 437 - 448.

 

FASS 1996. Läkemedelsinformation AB.

 

FOUQUE D, TAYEK JA, KOPPLE JD. Altered mental function during intravenous infusion of recombinant human insulin-like growth factor I. J Parenter Enter Nutr. 1995 19:231-233.

 

FREDHOLM BB, HELDIN C-H. Tillväxtfaktorer. Läkartidningen 1995 92:1454-1457.

 

FRYBURG DA. Insulin-like growth factor I exerts growth hormone – and insulin-like actions on human muscle protein metabolism. Am J Physiol 1994 267:E331-E336.

 

FRYBURG DA, JAHN LA, HILL SA, OLIVERAS DM, BARRETT EJ. Insulin and Insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms, J Clin Invest 1995 96:1722-1729.

 

GREENSPAN FS. Basic and clinical endocrinology. Appleton & Lange, East Norwalk, Conneticut, USA. 1991.

 

GUEVARA-AGUIRRE J, VASCONEZ O, MARTINEZ V, MARTINEZ AL, ROSENBLOOM AL, DIAMOND JR FB, GARGOSKY SE, NONOSHITA L, ROSENFELD RG. A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab 1995 80:1393-1398.

 

HALL K, BANG P, BRISMAR K. Insulinlikande tillväxtfaktor. Läkartidningen 1995 92:2666-2671.

 

JABRI N, SCHALCH DS, SCHWARTZ SL, FISCHER JS, KIPNES MS, RADNIK BJ, TURMAN NJ, MARCSISIN VS, GULER HP. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 1994 43:369-374.

 

LARON Z, KLINGER B. IGF-I treatment of adult patients with Laron Syndrome: preliminary results. Clin Endocrinol 1994 41:631-638.

 

LJUNGGREN Ö, LJUNGHALL S, LERNER U. Ständig ombyggnad pågår I skelettet. Läkartidningen 1995 92:2094-2100.

 

LUOMA TC. IGF-I, Possibly the most potent bodybuilding drug ever! And only a phone call away? Muscle Media 2000, Golden, Colorado, USA. 1995 Issue no. 44:118-121.

 

MALOZOWSKI S, STADEL B. Risks and benefits of insulin-like growth factor. Ann Intern Med 1994 121:549.

 

PHILLIPS WN. Doping-medicinbruk inom idrotten. Hilon förlag, Oslo. 1992 pp. 1-202.

 

ROSENFELD RG, GUEVARA-AGUIRRE J, GARGOSKY SE, ROSENBLOOM AL. IGF-I treatment of syndromes of growth hormone insensivity. In: Yhe insulin-like growth factors and their regulatory proteins, Proceedings of The Third International Symposium on Insulin-Like Growth Factors, Sydney, 6-10 February 1994, Excerpta medica, Amsterdam, Holland. 1994 pp 457-463.

 

THOBURN R. Insulin-like Growth Factor I. Drugs in Sports, MGD Press, Workworth, Ontario, Canada. 1995 3:12-15.

 

THOMPSON JL, BUTTERFIELD GE, MARCUS R, HINTZ RL, VAN LOAN M, GHIRON L, HOFFMAN AR. The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. J Clin Endocrinol Metab 1995 80:1845-1852.

 

UNDERWOOD LE, CLEMMONS DR. Prospects of therapy with IGF-I for catabolic conditions. In: The insulin-like growth factors and their regulatory proteins, Proceedings of The Third International Symposium on Insulin-Like Growth Factors, Sydney, 6-10 February 1994, Excerpta medica, Amsterdam, Holland. 1994 pp 449-456.

 

USALA AL. Risks and benefits of insulin-like growth factor. Ann Intern Med 1994 121:550.